Jefferies Initiates Beam Therapeutics with Buy Rating on Promising Gene Therapy Pipeline

Jefferies sets $41 price target for Beam Therapeutics, highlighting BEAM-302's potential as one-time treatment for rare genetic disease with $2.5B peak sales opportunity.